



**eunethta**  
EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT

EUnetHTA Joint Action 3 WP4

**“Rolling Collaborative Review” of COVID-19 treatments**

**HIGH-DOSE VITAMIN D FOR THE TREATMENT OF COVID-19**

**Project ID: RCR20**  
Monitoring Report

**Version 1.0, February 2021**

Template version November 2020



This Rolling Collaborative Review Living Document is part of the project / joint action '724130 / EUnetHTA JA3' which has received funding from the European Union's Health Programme (2014-2020)

## DOCUMENT HISTORY AND CONTRIBUTORS

Version	Date	Description of changes
V 0.1	04/02/2021	Literature searches, Literature screening, Data extraction
V 0.2	10/02/2021	Data extraction and analysis complete
V 0.3	11/02/2021	Check of data extraction and analysis
V 1.0	15/02/2021	First version

### Major changes from previous version

Chapter, page no.	Major changes from version [X.0]
	n.a.

### Disclaimer

The content of this “Rolling Collaborative Review” (RCR) represents a consolidated view based on the consensus within the Authoring Team; it cannot be considered to reflect the views of the European Network for Health Technology Assessment (EUnetHTA), EUnetHTA’s participating institutions, the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

### Rolling Collaborative Review team

Author(s)	Gesundheit Österreich GmbH (GÖG), Austria
-----------	---

## Further contributors

Project Management	
Zorginstituut Nederland (ZIN), Netherlands	Coordination between involved parties throughout the assessment
Austrian Institute for Health Technology Assessment (AIHTA), Austria	Coordination of RCR

## Conflict of interest

All authors and co-authors involved in the production of this living document have declared they have no conflicts of interest in relation to the technology and comparator(s) assessed according to the EUnetHTA declaration of interest (DOI) form. Conflict of Interest was evaluated following the [EUnetHTA Procedure Guidance for handling DOI form \(https://eunetha.eu/doi\)](https://eunetha.eu/doi).

## Copyright

EUnetHTA assessments are published under a “CC/BY/NC” [Creative Commons Licence](https://creativecommons.org/licenses/by-nc/4.0/).



## How to cite this assessment

Please cite this assessment as follows:

EUnetHTA Rolling Collaborative Review (RCR20) Authoring Team. High-Dose Vitamin D for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2021. [date of citation]. 34 pages. Report No.: RCR20, v1.0. Available from: [https //www.eunetha.eu](https://www.eunetha.eu).

Contact the EUnetHTA Secretariat [EUnetHTA@zinl.nl](mailto:EUnetHTA@zinl.nl) with inquiries about this assessment.

## TABLE OF CONTENTS

<b>DOCUMENT HISTORY AND CONTRIBUTORS</b> .....	<b>2</b>
<b>TABLE OF CONTENTS</b> .....	<b>4</b>
<b>LIST OF TABLES AND FIGURES</b> .....	<b>4</b>
<b>1 OBJECTIVE</b> .....	<b>6</b>
<b>2 METHODS</b> .....	<b>6</b>
2.1 SCOPE.....	6
2.2 SOURCES OF INFORMATION.....	8
<b>3 ABOUT THE TREATMENT</b> .....	<b>10</b>
3.1 MODE OF ACTION .....	10
3.2 REGULATORY STATUS .....	10
3.3 LEVEL OF EVIDENCE .....	11
<b>4 SUMMARY</b> .....	<b>11</b>
4.1 EFFECTIVENESS AND SAFETY EVIDENCE FROM RCTs.....	11
4.2 SAFETY EVIDENCE FROM OBSERVATIONAL STUDIES .....	11
4.3 ONGOING STUDIES.....	12
4.4 SCIENTIFIC CONCLUSION ABOUT STATUS OF EVIDENCE GENERATION .....	12
<b>5 REFERENCES</b> .....	<b>23</b>
<b>6 APPENDIX</b> .....	<b>25</b>
6.1 SEARCH STRATEGY TO IDENTIFY RANDOMISED CONTROLLED TRIALS.....	25
6.2 SEARCH STRATEGY TO IDENTIFY OBSERVATIONAL STUDIES.....	27
6.3 SEARCH STRATEGY TO IDENTIFY ONGOING STUDIES.....	31
6.4 FLOW DIAGRAMS .....	32

## LIST OF TABLES AND FIGURES

Table 2-1 Scope of the RCR .....	6
Table 4-1 Summary of findings (SoF) table for published RCTs related to effectiveness and safety of Vitamin D (calcifediol) compared to no Vitamin D for treating COVID 19.....	13
Table 4-2 Summary of findings (SoF) table for published RCTs related to effectiveness and safety of Vitamin D (cholecalciferol) compared to placebo for treating COVID19.....	13
Table 4-3 Study characteristics of included RCTs .....	14
Table 4-4 Ongoing trials of single agent: Vitamin D.....	18
Table 4-5 Ongoing trials of single agent: Vitamin D, continued .....	19
Table 4-6 Ongoing trials of single agent: Vitamin D, continued .....	20
Table 4-7 Ongoing trials of single agent: Vitamin D, continued .....	21
Table 4-8 Ongoing trials of single agent: Vitamin D, continued .....	22
Table 6-1 Search strategy to identify randomised controlled studies.....	25
Table 6-2 Search strategy to identify observational studies.....	27
Table 6-3 Search strategy to identify observational studies.....	28
Table 6-4 Search strategy to identify ongoing studies .....	31
Appendix Figure 6-1. Flow diagram depicting the selection process of RCTs.....	32
Appendix Figure 6-2. Flow diagram depicting the selection process of observational studies (January 2021) .....	33
Appendix Figure 6-3. Flow diagram depicting the selection process of observational studies (February 2021).....	34

## LIST OF ABBREVIATIONS

ARDS	Acute respiratory distress syndrome
AE	Adverse Event
CI	Confidence Interval
DOI	Declaration of interest
EUnetHTA	European Network of Health Technology Assessment
GÖG	Gesundheit Österreich GmbH
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
HR	Hazard Ratio
ICD	International Classification of Diseases
MD	Mean Difference
MeSH	Medical Subject Headings
NA	Not applicable
NR	Not reported
OR	Odds Ratio
RCT	Randomized Controlled Trial
RCR	Rolling Collaborative Review
REA	Relative Effectiveness Assessment
RR	Relative Risk
SAE	Serious Adverse Event
SD	Standard Deviation
SMD	Standardized Mean Difference
WP4	Work Package 4
VDR	Vitamin D-receptors

## 1 OBJECTIVE

The aim of this EUnetHTA Rolling Collaborative Review is

- to inform health policy at the national/regional and at the European level at an early stage in the life-cycle of therapies which interventions are currently undergoing clinical trials,
- to monitor (ongoing studies and their results) permanently - in the format of a Living Document - potential therapies against COVID-19,
- to present comparative data on effectiveness and safety of potential therapies and
- to support preparations for an evidence-based purchasing of regional/ national health politicians, if necessary.

To avoid redundancies and duplication, the EUnetHTA Rolling Collaborative Review will reuse sources from international initiatives to collect information and data on COVID-19 treatments.

The scope of the Rolling Collaborative Review is of descriptive nature. These **EUnetHTA Rolling Collaborative Reviews are not meant to substitute a joint Relative Effectiveness Assessment (REA)** adhering to the agreed procedures and aiming at critical appraisal of the clinical evidence based on the Submission Dossier submitted by the (prospective) Marketing Authorization Holder (MAH).

## 2 METHODS

This Rolling Collaborative Review is prepared according to the project plan (“Rolling Collaborative Review (RCR) on Covid-19 treatments: Project description and planning”, published [on the EUnetHTA website](#)) and will be updated monthly. Monthly updates are published on the EUnetHTA Covid-19 Website (<https://eunetha.eu/covid-19-treatment/>) and on the EUnetHTA Rolling Collaborative Review Sharepoint page each 15<sup>th</sup> of the month.

### 2.1 Scope

**Table 2-1 Scope of the RCR**

Description	Project Scope
Population	<p><b>Disease</b></p> <ul style="list-style-type: none"> <li>• SARS-CoV-2 is a novel coronavirus causing a respiratory illness termed COVID-19. The full spectrum of COVID-19 ranges from mild, self-limiting respiratory tract illness to severe progressive pneumonia, multi-organ failure, and death.</li> </ul> <p><b>ICD-Codes</b> (<a href="https://www.who.int/classifications/icd/covid19/en">https://www.who.int/classifications/icd/covid19/en</a>)</p> <ul style="list-style-type: none"> <li>• An emergency ICD-10 code of ‘U07.1 COVID-19, virus identified’ is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.</li> <li>• An emergency ICD-10 code of ‘U07.2 COVID-19, virus not identified’ is assigned to a clinical or epidemiological diagnosis of COVID-19 where laboratory confirmation is inconclusive or not available.</li> <li>• Both U07.1 and U07.2 may be used for mortality coding as cause of death. See the International guidelines for certification and classification (coding) of COVID-19 as cause of death following the link below.</li> <li>• In ICD-11, the code for the confirmed diagnosis of COVID-19 is RA01.0 and the code for the clinical diagnosis (suspected or probable) of COVID-19 is RA01.1.</li> </ul> <p><b>MeSH-terms</b></p> <ul style="list-style-type: none"> <li>• COVID-19, Coronavirus Disease 2019</li> </ul> <p><b>Target population</b> (<a href="https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/">https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/</a>)</p>

	<ul style="list-style-type: none"> <li>Asymptomatic or pre-symptomatic Infection: Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.</li> <li>Mild Illness: Individuals who have any of the various signs and symptoms of COVID 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging.</li> <li>Moderate Illness: Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO<sub>2</sub>) ≥94% on room air at sea level.</li> <li>Severe Illness: Individuals who have respiratory frequency &gt;30 breaths per minute, SpO<sub>2</sub> &lt;94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) &lt;300 mmHg, or lung infiltrates &gt;50%.</li> <li>Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.</li> </ul>
<b>Intervention</b>	<ul style="list-style-type: none"> <li>Substances: Vitamin D<sub>2</sub> (ergocalciferol), vitamin D<sub>3</sub> (cholecalciferol) and their metabolites ercalcidiol, calcifediol, calcitriol and ercalcitriol*</li> <li>Dosing: “high-dose” interventions greater than 4,000 IU per day**</li> </ul>
<b>Comparison</b>	<p>Any active treatment, placebo, or standard of care.</p> <p><b>Rationale:</b> Since there is no gold standard treatment any comparator is acceptable as well as the above listed interventions.</p>
<b>Outcomes</b>	<p><u>Main outcome:</u></p> <ul style="list-style-type: none"> <li>All-cause Mortality (Survival)</li> </ul> <p><u>Additional Outcomes:</u></p> <p>Efficacy:</p> <ul style="list-style-type: none"> <li>Length of hospital stay,</li> <li>Viral burden (2019-nCoV RT-PCR negativity),</li> <li>Clinical progression (WHO Clinical Progression Scale measured daily over the course of the study),</li> <li>Rates of hospitalization and of patients entering ICU,</li> <li>Rates and duration of mechanical ventilation,</li> <li>Quality of life.</li> </ul> <p>Safety:</p> <ul style="list-style-type: none"> <li>Adverse events (AE),</li> <li>Severe adverse events (SAE),</li> <li>Withdrawals due to AEs,</li> <li>Most frequent AEs,</li> <li>Most frequent SAEs.</li> </ul> <p><b>Rationale:</b> We will give priority according to the Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102592/pdf/main.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102592/pdf/main.pdf</a>) and A minimal common outcome measure set for COVID-19 clinical research from the WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection.</p>
<b>Study design</b>	<p>Efficacy: randomised controlled trials (RCT)</p> <p>Safety: observational studies (comparative or single-arm prospective studies and registries)</p>

\* Combined interventions of vitamin D and other substances are included if the interventions in two trial arms differ only by the presence or absence of vitamin D. \*\* There is no consensus definition of “high-dose” vitamin D. The adequate intake for adults recommended by EFSA is 600 IU/day, assuming minimal cutaneous production. [1] Various medical societies recommend different daily intake doses, including 2,000 IU or more. Generally, the upper intake level for Vitamin D can be assumed at 4,000 IU per day and continuing supplementation exceeding this level is recommended against by many experts. [2] We therefore provisionally applied this threshold to define “high-dose” vitamin D treatment. In the current version of the report, no published RCTs were excluded because of the dosing of vitamin D. One observational study was excluded that investigated a cohort of patients that had been using vitamin D supplementation at an average dosage of 1,800 IU/day.

## 2.2 Sources of information

According to the project plan, this Rolling Collaborative Review is based on three main sources of information, as described below:

### 1. Summary of findings (SoF) table for published RCTs related to effectiveness and safety:

Deviating from the other RCRs, this table is not based on the living systematic review and Network Meta-Analysis (NMA) created by the partnering institute of DEPLazio ([find the PROSPERO protocol here](#)).

The literature search is conducted in the following databases:

- MEDLINE, accessed via OVID
- PubMed

To identify preprints of preliminary reports of work that have not been peer-reviewed, the following sources are searched:

- medRxiv Health Sciences
- bioRxiv Biology
- arXiv

In addition to the sources and strategies described above, registers of ongoing studies are screened. Appendix Table 6-1 describes in detail the sources searched, the search terms used and the dates at which the searches are executed.

### Literature selection, data extraction, risk of bias assessment, data synthesis, certainty of evidence:

At least two reviewers are independently screening search results and assessing full texts of studies according to the pre-defined criteria (see Table 2-1), with disagreements solved by discussion with a third member of the review team. One reviewer extracts study characteristics and outcome data. Studies investigating a combination of vitamin D and other dietary supplements or medicines versus a comparator that does not include this combination therapy are excluded. Data extraction is checked by a second reviewer. The process of study selection is depicted as a flow diagram in Appendix Figure 6-1. Two authors independently assess the risk of bias of the included studies using the Cochrane RoB tool v2.0 [3,4]. Dichotomous outcomes are analysed by calculating the relative risk (RR) for each trial with the uncertainty in each result being expressed by its 95% confidence interval (CI). Continuous outcomes are analysed by calculating the mean difference (MD) with the relative 95% CI when the study used the same instruments for assessing the outcome. The standardised mean difference (SMD) is applied when studies used different instruments. Two reviewers independently use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [5], to evaluate the certainty of evidence.

### 2. Table(s) on published (peer reviewed) observational studies for safety results:

The literature search is conducted on a monthly basis. For version 1.0 of this report, the search was conducted in a two-step-process, in January and February 2021. The sources and search methods are described in more detail in Appendix Table 6-2 and Table 6-3.

<b>Population</b>	See project Scope
<b>Intervention</b>	<ul style="list-style-type: none"><li>• Substances: Vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol) and their metabolites ercalcidiol, calcifediol, calcitriol and ercalcitriol*</li></ul>

	<ul style="list-style-type: none"> <li>• Dosing: “high-dose” interventions greater than 4,000 IU per day**</li> </ul>
<b>Comparison</b>	Any active treatment, placebo, or standard of care.
<b>Outcomes</b>	See project Scope
<b>Study design</b>	<p>Inclusion criteria: Prospective non-randomised controlled trials, prospective case series (i.e. comparative or single-arm prospective studies), registries</p> <p>Exclusion criteria: retrospective studies, case studies/ case reports, observational studies that do not report safety data</p>

\* Combined interventions of vitamin D and other substances are included if the interventions in two trial arms differ only by the presence or absence of vitamin D. \*\* There is no consensus definition of “high-dose” vitamin D. The adequate intake for adults recommended by EFSA is 600 IU/day, assuming minimal cutaneous production. [1] Various medical societies recommend different daily intake doses, including 2,000 IU or more. Generally, the upper intake level for Vitamin D can be assumed at 4,000 IU per day and continuing supplementation exceeding this level is recommended against by many experts. [2] We therefore provisionally applied this threshold to define “high-dose” vitamin D treatment. In the current version of the report, no published RCTs were excluded because of the dosing of vitamin D. One observational study was excluded that investigated a cohort of patients that had been using vitamin D supplementation at an average dosage of 1,800 IU/day.

Two researchers from NIPHNO carry out title and abstract screening and assess the full texts of all potentially eligible studies. The study selection process is depicted in a flow diagram (Appendix Figure 6-2 and Appendix Figure 6-3). One researcher of GÖG extracts the data and assesses the risk of bias using Robins-I (<https://training.cochrane.org/handbook/current/chapter-25>).

Results are presented in tabular form for all included studies.

### 3. Table(s) on ongoing trials:

The following clinical trial registries are searched on a monthly basis:

- ClinicalTrials.gov: <https://clinicaltrials.gov/>
- ISRCTN: <https://www.isrctn.com/>
- European Clinical Trials Registry: <https://www.clinicaltrialsregister.eu/>

Inclusion criteria: Randomised controlled trials, Controlled trials

One researcher of GÖG is searching and extracting the data for the eligible studies. At least two reviewers are independently screening search results, with disagreements solved by discussion with a third member of the review team. At the drafting stage of each update, the author team verifies whether the status of previously identified studies has changed. This is done by verifying the date of the last update posted in the trial registers. In addition, trial register IDs of all previously identified studies are entered in both PubMed and Google (google.com) to verify if previously identified studies have been published since the last update. In Google, the first 10 hits are screened for this purpose.

Search methods are described in more detail in Appendix Table 6-4. Data are presented in tabular form.

## 3 ABOUT THE TREATMENT

### 3.1 Mode of Action

Vitamin D is a generic term used for a group of seco-sterols, mostly referring to vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) and their metabolites. Both vitamins can be taken up by diet, whereas vitamin D3 is also produced endogenously from 7-dihydrocholesterol in sun-exposed skin. After absorption, vitamin D2 and D3 undergo hepatic and renal hydroxylation into 25-OH-D2 (ercalcidiol) and 25-OH-D3 (calcifediol) and hereafter into the biologically active forms 1,25-OH<sub>2</sub>-D2 (ercalcitriol) and 1,25-OH<sub>2</sub>-D3 (calcitriol). The effects of vitamin D are mediated through binding on vitamin D-receptors (VDR). [6,7]

In addition to the well-studied role of vitamin D in bone metabolism, it also modulates several immunomodulatory pathways both in the innate and adaptive immune system (VDR are, for example, expressed on macrophages, dendritic cells, T-cells, and B-cells). Vitamin D generally maintains a balance between effector responses and inflammatory processes. [6]

In acute infections, vitamin D plays a role in enhancing the innate immune system to defend against pathogens by immune cell activation and proliferation (macrophages, neutrophils, dendritic cells) resulting in controlled release of proinflammatory cytokines and antimicrobial peptides like cathelicidin. The role of vitamin D in initial immune response is physiologically beneficial and may also be relevant in COVID-19 infections.

However, excessive immune reactions, like acute respiratory distress syndrome (ARDS) in COVID-19, can result in cytokine storm, strong inflammation and herewith tissue damaging. It is postulated that vitamin D limits these destructive pathways by modulating adaptive and innate immune response towards anti-inflammatory, anti-proliferative processes. [8,9] In addition, vitamin D might interfere with viral entry into the host cells by downregulating ACE2 expression. [10,11]

### 3.2 Regulatory Status

The mutual recognition information (MRI) index<sup>1</sup> hosted by the Heads of Medicines Agencies (HMA) network of the EU lists 65 approved vitamin D-containing mono-preparations that may be marketed in the member states under different domestic market names. Of those, 54 contain cholecalciferol, 8 calcitriol (capsules; 0.25 and 0.5 µg), 2 calcifediol (capsules; 30 and 270 µg) and 1 ergocalciferol (capsules; 50,000 IU). Cholecalciferol-containing preparations are available as capsules or tablets (various strengths between 400 and 100,000 IU), oral drops/solution (various strengths between 2,740 and 20,000 IU/ml), and effervescent granules (440 IU per sachet). In addition, there are several combination preparations of cholecalciferol with calcium carbonate, calcium phosphate or bisphosphonates (used for the treatment of bone turnover disorders).

In addition to medicinal products, vitamin D may be marketed in the EU as food supplement.<sup>2</sup> These products can be marketed in several forms, such as capsules, powders or liquids and may contain either cholecalciferol or ergocalciferol. However, article 6 of the directive mandates that 'The labelling, presentation and advertising must not attribute to food supplements the property of preventing, treating or curing a human disease, or refer to such properties.'

---

<sup>1</sup> <https://mri.cts-mrp.eu/Human/>

<sup>2</sup> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Available at: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02002L0046-20170726#B-6>

### **3.3 Level of Evidence**

The evidence for vitamin D for treatment of COVID-19 is still in early stage. There is currently no standardized or recommended level of what constitutes a (beneficial) “high dose”. Three RCTs [12-14] of varying size and quality have been published to date (one so far only as preprint [13]). We moreover identified 19 ongoing RCTs with estimated primary completion dates ranging from June 2020 to February 2023 (7 in 2020, 8 in 2021, 1 in 2022, 1 in 2023, 2 entries have no information on study completion date).

## **4 SUMMARY**

### **4.1 Effectiveness and Safety evidence from RCTs**

Two RCTs investigate vitamin D3 administered in the form of cholecalciferol [13,14] and one investigates vitamin D3 administered in the form of calcifediol [12]. One of the cholecalciferol trials [14] included only patients with mild or asymptomatic COVID-19 and vitamin D deficiency (25 (OH)D level < 20 ng/ml) and compared vitamin D3 with placebo. In the other two RCTs, patients hospitalized with (severe) COVID-19 were included and vitamin D3 was administered in addition to standard care. One of these trials compared vitamin D3 to placebo plus standard care [13], the other compared to standard care only [12]. While Murai et al. [13], who in sum included 240 patients, conducted a post hoc analysis with regard to a subgroup of 116 patients with vitamin D deficiency (25 (OH)D level < 20 ng/ml), no information on the proportion of patients with vitamin D deficiency was available in Castillo et al. [12]. Because of the differences between studies regarding intervention (form and dosing, see also below) and population, results could not be pooled.

Rastogi et al. [14] used a dosage of 60,000 IU cholecalciferol daily during the first week and thereafter weekly for those with 25(OH)D > 50 ng/ml (and continuing daily for the others). They report 10 of 16 patients in the cholecalciferol group reaching SARS-CoV-2 negativity (primary outcome) before week 3 compared to 5 of 24 patients in the placebo group. SARS-CoV-2 negativity was determined by PCR but no cut-off Ct-value was reported. They do not report baseline characteristics on important risk factors such as obesity. Also, sample size calculation was done with regard to the secondary outcome (serum level of inflammatory marker).

Castillo et al. [12] used a dosage of 0.532 mg calcifediol on day 1, 0.266 mg on day 3 and 7, then weekly until discharge or admission to intensive care unit. They conducted an open label pilot trial with 76 patients. The study publication refers to a planned bigger trial with over 1,000 patients, registered in ClinicalTrials.gov (NCT04366908) with an estimated study completion date in August 2020. However, no publication could be found. They report only 1 of 50 calcifediol patients requiring admission to intensive care unit compared to 13 of 26 patients in the control group. Two patients died in the control group, none in the calcifediol group. These results remained statistically significant when adjusted for the two risk factors with significant baseline differences, hypertension and diabetes mellitus type 2. However, data on obesity were not collected (nor on vitamin D deficiency, see above).

Murai et al. [13] used a single dose of 200,000 IU cholecalciferol. They report on four relevant outcomes, mortality, length of hospital stay, admission to intensive care unit and mechanical ventilation. They find no significant effects in either direction, neither in the overall group, nor in the subgroup with vitamin D deficiency.

None of the RCTs reported (severe) adverse events.

### **4.2 Safety evidence from observational studies**

No observational study on safety fulfilling inclusion criteria was identified.

### **4.3 Ongoing studies**

179 hits were retrieved from database search, 160 of which remained after deduplication. Of these, 19 hits were included.

### **4.4 Scientific conclusion about status of evidence generation**

Currently, the evidence for vitamin D for COVID-19 is still in early stage, but a considerable number of studies is ongoing. The three published RCTs are heterogeneous with regard to the form and dosage of vitamin D, baseline disease severity and risk factors (with relevant risk factors not always being reported/available). Overall, results are inconsistent.

**Table 4-1 Summary of findings (SoF) table for published RCTs related to effectiveness and safety of Vitamin D (calcifediol) compared to no Vitamin D for treating COVID 19**

Outcome	Anticipated absolute effects (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with no Vitamin D	Risk with Vitamin D (calcifediol)				
<b>All-cause Mortality</b> Population: consecutive patients hospitalized with COVID-19 infection	77 per 1,000	0 per 1,000	not estimable	76 (1 RCT[12])	⊕○○○ VERY LOW	No deaths in the Vitamin D group
<b>ICU admission</b> Population: consecutive patients hospitalized with COVID-19 infection	500 per 1,000	480 fewer per 1,000 (from 497 fewer to 356 fewer)	RR 0.040 (0.006 to 0.289)	76 (1 RCT [12])	⊕⊕○○ LOW	Own calculation of RR based on reported frequencies

**Abbreviations:** [CI]=[Confidence interval]; [HR]=[Hazard Ratio]; [ICU]=[intensive care]; [RR]=[Risk ratio].

**Table 4-2 Summary of findings (SoF) table for published RCTs related to effectiveness and safety of Vitamin D (cholecalciferol) compared to placebo for treating COVID19**

Outcome	Anticipated absolute effects (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with placebo	Risk with Vitamin D (cholecalciferol)				
<b>All-cause Mortality</b> Population: hospitalised patients with severe COVID-19	50 per 1,000	17 more per 1,000 (from 26 fewer to 136 more)	RR 1.333 (0.477 to 3.727)	240 (1 RCT [13])	⊕○○○ VERY LOW	Own calculation of RR based on reported frequencies
<b>Length of hospital stay</b> Population: hospitalised patients with severe COVID-19	-	-	HR 1.12 (0.90 to 1.50)	240 (1 RCT [13])	⊕⊕○○ LOW	
<b>Viral burden (SARS-CoV-2 negativity)</b> Population: mild or asymptomatic COVID-19	208 per 1,000	417 more per 1,000 (from 54 more to 1,000 more)	RR 3.000 (1.260 to 7.142)	40 (1 RCT [14])	⊕○○○ VERY LOW	Own calculation of RR based on reported frequencies
<b>ICU admission</b> Population: hospitalised patients with severe COVID-19	208 per 1,000	50 fewer per 1,000 (from 116 fewer to 63 more)	RR 0.760 (0.443 to 1.304)	240 (1 RCT [13])	⊕⊕○○ LOW	Own calculation of RR based on reported frequencies

Outcome	Anticipated absolute effects (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Certainty of evidence	Comments
	Risk with placebo	Risk with Vitamin D (cholecalciferol)				
<b>Mechanical ventilation</b> Population: hospitalised patients with severe COVID-19	142 per 1,000	75 fewer per 1,000 (from 112 fewer to 7 more)	RR 0.471 (0.211 to 1.049)	240 (1 RCT [13])	⊕○○○ VERY LOW	Own calculation of RR based on reported frequencies

**Abbreviations:** [CI]=[Confidence interval]; [HR]=[Hazard Ratio]; [ICU]=[intensive care]; [RR]=[Risk ratio].

**Table 4-3 Study characteristics of included RCTs**

Author, year, reference number/Study name/Study ID	Rastogi 2020 [14], NCT04459247 (SHADE)	Murai 2020 [13], NCT04449718	Castillo 2020 [12], NCT04366908*
<b>Study design</b>	RCT	RCT	Pilot RCT, open label
<b>Centres (single centre or multicentre), country, setting</b>	Single centre, India, tertiary care hospital	Multicentre, Brazil, one quarternary hospital and one field hospital in Sao Paulo	Single centre, Spain, university hospital
<b>Patient population (number of included patients/ Mean age and sex/ Disease severity†)</b>	n=40‡,  Intervention group: age (median, IQR): 50.0 (36-51); gender (% male): 37.5%  Comparator group: age (median, IQR): 47.5 (39.3-49.2); gender (% male): 58.3%  Severity: mild or asymptomatic COVID-19	n=240 age (mean, SD): 56.3 (14.6) gender (% male): 56.3% Severity: hospitalised patients with severe COVID-19	n=76 age (mean, SD): 53+/-10 gender (% male): 59.2% Severity: consecutive patients hospitalized with COVID-19 infection
<b>Inclusion criteria</b>	Individuals with SARS-CoV-2 infection who were mildly symptomatic or asymptomatic with or without	<ul style="list-style-type: none"> <li>adults aged 18 years or older</li> </ul>	<ul style="list-style-type: none"> <li>consecutive patients hospitalized with COVID-19 infection (acute respiratory infection, confirmed by a</li> </ul>

\* refers to a planned RCT with estimated study completion date in August 2020, for which no publication could be identified – Castillo 2020 report the results of a preceding pilot trial

† Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

‡ Age and sex not reported for whole cohort

	<p>comorbidities (hypertension, diabetes mellitus, chronic obstructive airway disease, chronic liver disease, chronic kidney disease) Patients with vitamin D deficiency defined as 25 (OH)D level &lt; 20 ng/ml<sup>§</sup></p>	<ul style="list-style-type: none"> <li>• diagnosis of COVID-19 by either polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from nasopharyngeal swabs or computed tomography scan findings (bilateral multifocal ground-glass opacities ≥ 50%) compatible with the disease</li> <li>• diagnosis of flu syndrome with hospitalization criteria on hospital admission, presenting respiratory rate ≥ 24 breaths per minute, saturation &lt; 93% on room air or risk factors for complications, such as heart disease, diabetes mellitus, systemic arterial hypertension, neoplasms, immunosuppression, pulmonary tuberculosis, and obesity, followed by COVID-19 confirmation before randomization</li> </ul>	<p>radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB-65 severity scale recommending hospital admission in case of total score &gt; 1)</p>
<p><b>Exclusion criteria</b></p>	<p>Rastogi 2020: Patients unable to take oral supplementation like those requiring invasive ventilation or with significant comorbidities like uncontrolled hyperglycaemia or hypertension were excluded.**</p>	<ul style="list-style-type: none"> <li>• patient unable to read and sign the written informed consent</li> <li>• patient already admitted under invasive mechanical ventilation</li> <li>• previous vitamin D3 supplementation (&gt; 1,000 IU/day)</li> <li>• renal failure requiring dialysis or creatinine ≥ 2.0 mg/dL</li> <li>• hypercalcemia defined by total calcium &gt; 10.5 mg/dL</li> <li>• pregnant or lactating women</li> </ul>	<ul style="list-style-type: none"> <li>• Patients younger than 18 years and pregnant women</li> </ul>

<sup>§</sup> not consistent with study registry mentioning only „SARS-CoV-2 RNA positive Asymptomatic individuals“

\*\* slight inconsistencies with criteria in study registry: “Uncontrolled Diabetes Uncontrolled Hypertension Chronic Liver Disease Chronic obstructive Pulmonary disease Requiring Invasive Ventilation”

		<ul style="list-style-type: none"> <li>patients with expected hospital discharge in less than 24 hours</li> </ul>	
<b>Intervention</b> <b>(generic drug name and dosage, time frame; number of randomized/ enrolled patients in subgroups - Mild, Moderate, Severe, Critical COVID-19)</b>	<p>Cholecalciferol (day 1-7: 60,000 IU per day (5 ml oral solution in nano droplet form), day 8-14: weekly 60,000 IU cholecalciferol to those with 25(OH)D &gt;50 ng/ml or else continued daily 60,000 IU cholecalciferol)</p> <p>n=16, no subgroups reported</p>	<p>Cholecalciferol (single dose of 200,000 IU of dissolved in a 10 mL of peanut oil solution on day of randomization plus standard care<sup>††</sup>)</p> <p>n=120 (randomised), n=117 (per protocol), all severe to critical, no subgroups reported</p>	<p>Calcifediol (0.532 mg on day 1, 0.266 mg on day 3 and 7, then weekly until discharge or ICU admission plus standard care as per hospital protocol (see below)</p> <p>n=50, no subgroups reported</p>
<b>Comparator(s)</b> <b>(standard care or generic drug name and dosage, time frame; number of randomized/ enrolled patients in subgroups - Mild, Moderate, Severe, Critical COVID-19)</b>	<p>Placebo (5 ml distilled water) for 7 days</p> <p>n=24, no subgroups reported</p>	<p>Placebo (10 mL of peanut oil solution plus standard care<sup>††</sup>)</p> <p>n=120 (randomised), n= 118 (per protocol), all severe to critical, no subgroups reported</p>	<p>Standard care as per hospital protocol (hydroxychloroquine 400 mg every 12 h on the first day, and 200 mg every 12 h for the following 5 days combined with azithromycin 500 mg orally for 5 days; for patients with pneumonia and NEWS <math>\geq</math> 5 additionally ceftriaxone 2 g intravenously every 24 h for 5 days)</p> <p>n=26, no subgroups reported</p>
<b>Primary Outcome(s)</b>	<ul style="list-style-type: none"> <li>Proportions of participants who turn SARS-CoV-2 negative (confirmed twice at 24-hour interval) before week 3 in the two groups</li> </ul>	<ul style="list-style-type: none"> <li>Hospital length of stay, defined as the total number of days that patients remained hospitalized from the date of study admission until the date of hospital discharge or death<sup>§§</sup></li> </ul>	<ul style="list-style-type: none"> <li>Rate of ICU admission</li> <li>mortality</li> </ul>
<b>Patient-relevant secondary outcome(s)</b>	NR	<ul style="list-style-type: none"> <li>mortality</li> <li>number of patients admitted to ICU</li> <li>number of patients who needed mechanical ventilation and duration of mechanical ventilation</li> </ul>	NR

<sup>††</sup> no further definition

<sup>††</sup> no further definition

<sup>§§</sup> The criteria used for patient discharge were: 1) no need for supplemental oxygen in the last 48 hours; 2) no fever in the last 72 hours; and 3) oxygen saturation > 93% in room air without respiratory distress

		(ClinicalTrials.gov: In addition “Number and severity of symptoms” and Physical activity Baecke questionnaire” are mentioned)	
<b>Follow-up (days, months)</b>	21 days (oropharyngeal swabs and SARS-CoV-2 RNA detection by PCR on days 5, 7, 10, 14, 18, 21)	Outcomes were assessed at baseline and on hospital discharge or death records.	Until ICU admission, hospital discharge or death
<b>Sponsor/ lead institution</b>	Department Of Internal Medicine, Nehru Hospital, PGIMER, Chandigarh 160012, India The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.	Clinical Hospital of the School of Medicine of the University of Sao Paulo, Ibirapuera Field Hospital supported by Sao Paulo Research Foundation (grants 20/05752-4; 19/24782-4; 20/11102-2; 16/00006-7; 17/13552-2; 15/26937-4; 19/18039-7) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (305556/2017-7).	Maimónides Biomedical Research Institute of Córdoba public funding (COVID-011-2020 Programa de Investigación clínica en COVID-19 de Andalucía, Consejería de Salud y Familia, Fundacion Progreso y Salud, Fundacion para la Investigacion Biomedica de Cordoba)

**Abbreviations:** [CURB]=[Confusion, Urea, Respiratory rate, Blood pressure]; [ICU]=[Intensive Care Unit]; [IU]=[international unit]; [mg]=[milligram]; [ml]=[per millilitre]; [NEWS]=[National Early Warning Score]; [ng]=[nanogram]; [NR]=[not reported]; [RCT]=[randomised clinical trial]

**Table 4-4 Ongoing trials of single agent: Vitamin D**

<b>Trial Identifier/registry ID(s)/contact</b>	IRCT20200324046850N1	NCT04344041	NCT04621058	NCT04536298
<b>Estimated study completion date</b>	No information	May 2021	November 2021	April 2021
<b>Study design, study phase</b>	RCT, phase 3	RCT, phase 3	RCT, phase 3	RCT, phase 3
<b>Recruitment status</b>	Recruitment complete	Recruiting	Recruiting	Recruiting
<b>Number of Patients, Disease severity*</b>	100 patients diagnosed with COVID-19	260 high-risk COVID-19 Patients	108 patients with COVID-19 and pneumonia	2,700 Patients newly diagnosed with COVID-19 (inclusion within 72 hours of testing)
<b>Setting (hospital, ambulatory...)</b>	Hospital	Hospital, ambulatory, nursing home	Hospital	Ambulatory
<b>Intervention (generic drug name and dosage)</b>	Standard country protocol drugs with vitamin D3 ampoules of 50,000 units once a week and N-acetylcysteine placebo tablets every 12 hours***	High dose of vitamin D3 Drug: cholecalciferol 200,000 IU	If vitamin D deficiency < 30 ng/ml: treatment with 2 capsules of 0.266 mg  If vitamin D deficiency < 40 ng/ml: treatment with 1 capsule of 0.266 mg	Vitamin D capsules including 3,200 IU of vitamin D3. Three capsules per day (9,600 IU/day) will be taken on days 1 and 2, and one capsule per day (3,200 IU/day) will be taken on days 3 through 28
<b>Comparator (standard care or generic drug name and dosage)</b>	Standard country protocol drugs with placebo vitamin D3 once a week and placebo tablets N-acetylcysteine every 12 hours†††	Standard dose of vitamin D3, drug: cholecalciferol 50,000 IU	Placebo	Placebo
<b>Primary Outcome(s)</b>	Time to clinical improvement	Mortality	Mortality	Hospitalization or death in index cases
<b>Sponsor/ lead institution, country (also country of recruitment if different)</b>	Abadan University of Medical Sciences, Iran	CHU Angers, France	Bioaraba Health Research Institute Fundación Eduardo Anitua, Spain	Brigham and Women's Hospital

\*Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

**Abbreviations:** [RCT]=[randomised clinical trial]; [IU]=[international unit]; [ICU]=[Intensive Care Unit]; [ng/ml]=[nanograms per millilitre]; [mg]=[milligram]

\*\*\* only relevant study arm displayed

††† only relevant study arm displayed

**Table 4-5 Ongoing trials of single agent: Vitamin D, continued**

<b>Trial Identifier/registry ID(s)/contact</b>	NCT04552951	NCT04641195	EudraCT: 2020-001960-28	NCT04363840
<b>Estimated study completion date</b>	December 2020	December 2021	No information	December 2020
<b>Study design, study phase</b>	RCT, phase 4	RCT, phase 3	RCT, phase 3	RCT, phase 2
<b>Recruitment status</b>	Recruiting	Not yet recruiting	Not information, ongoing study	Not yet recruiting
<b>Number of Patients, Disease severity*</b>	80 patients diagnosed with COVID-19	700 patients diagnosed with COVID-19	108 patients diagnosed with COVID-19	1,080 patients newly diagnosed with COVID-19 (within 24 hours after diagnoses)
<b>Setting (hospital, ambulatory...)</b>	Not clear	Start as inpatient, continuation as outpatients	Hospital	Ambulatory
<b>Intervention (generic drug name and dosage)</b>	Cholecalciferol Single dose of 100,000 IU	Vitamin D3 (cholecalciferol) 180,000 international units (IU) of vitamin D3 at enrolment, followed by 2,000 IU once per day from enrolment to 8 weeks <sup>‡‡</sup>	Hydroferol 0.266 mg capsules	Aspirin 81 mg to be taken orally once daily for 14 days. In combination with Dietary Supplement: Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
<b>Comparator (standard care or generic drug name and dosage)</b>	No intervention / no vitamin D	Placebo	Placebo	Aspirin 81 mg to be taken orally once daily for 14 days.
<b>Primary Outcome(s)</b>	<ul style="list-style-type: none"> <li>• Mortality</li> <li>• ICU admission</li> <li>• Time of hospitalization <sup>§§§</sup></li> </ul>	Time to recovery	Mortality ICU admission	Hospitalization
<b>Sponsor/ lead institution, country (also country of recruitment if different)</b>	Fundación para la Investigación Biosanitaria del Principado de Asturias, Spain	Harvard School of Public Health, US Recruitment: India	Investigation Institute Bioaraba, Spain	Louisiana State University Health Sciences Center in New Orleans, US

\*Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

Abbreviations: [RCT]=[randomised clinical trial]; [IU]=[international unit]; [ICU]=[Intensive Care Unit]

<sup>‡‡</sup> only relevant study arm displayed, additional study arms for treatment with Zinc and treatment with zinc in combination with Vitamin D

<sup>§§§</sup> only relevant primary outcome measures displayed

**Table 4-6 Ongoing trials of single agent: Vitamin D, continued**

<b>Trial Identifier/registry ID(s)/contact</b>	NCT03188796	NCT04525820	CTRI/2020/06/026189
<b>Estimated study completion date</b>	February 2023	June 2021	February 2022
<b>Study design, study phase</b>	RCT, phase 3	RCT, Phase: no information	RCT, phase 2
<b>Recruitment status</b>	Recruiting	Recruiting	Not yet recruiting
<b>Number of Patients, Disease severity*</b>	2400 critical ill patients including patients infected with COVID-19	80 hospitalized patients diagnosed with COVID-19	210 patients with mild to moderate COVID- 19
<b>Setting (hospital, ambulatory...)</b>	Hospital, ambulatory	Hospital	COVID care facility
<b>Intervention (generic drug name and dosage)</b>	Cholecalciferol oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4,000 IU) for 90 days	Single high dose vitamin D one dose orally of 140,000 IU (7 ml) followed by vitamin D 800 IU per day (treatment as usual)	Standard COVID-19 treatment, and Vitamin D 400,000 IU single dose plus Magnesium Glycinate 250 mg BD for 14 days
<b>Comparator (standard care or generic drug name and dosage)</b>	Placebo	Single dose of a placebo solution followed by vitamin D 800 IU per day (treatment as usual)	Standard COVID-19 treatment, and Vitamin D 60,000 IU single dose plus Magnesium Glycinate 250mg BD for 14 days
<b>Primary Outcome(s)</b>	Mortality	Length of hospitalization	<ul style="list-style-type: none"> <li>• Negative RT- PCR test for COVID 19 infection</li> <li>• Improvement in Signs and symptoms of COVID 19 infection, use of ventilator, length of stay in ICU</li> <li>• Reduction in CRP levels</li> <li>• Reduction in rate of COVID -19 complication.</li> <li>• Speed of recovery and duration to becoming asymptomatic</li> </ul> Length of hospital stay
<b>Sponsor/ lead institution, country (also country of recruitment if different)</b>	Medical University of Graz, Austria	Prof. Dr. Jörg Leuppi, Cantonal Hospital Baselland Liestal, Switzerland	Suraksha Pharma Private Limite, India

\*Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

**Table 4-7 Ongoing trials of single agent: Vitamin D, continued**

<b>Trial Identifier/registry ID(s)/contact</b>	NCT04334005	NCT04489628	NCT04385940	NCT04636086
<b>Estimated study completion date</b>	June 2020	August 2021	December 2020	February 2021
<b>Study design, study phase</b>	RCT, Phase: no information	RCT, Phase 1	RCT, Phase 3	RCT, Phase 4
<b>Recruitment status</b>	Not yet recruiting	Not yet recruiting	Not yet recruiting	Recruiting
<b>Number of Patients, Disease severity*</b>	200 non-severe symptomatic patients diagnosed with COVID-19	110 patients diagnosed with COVID-19 and present asymptomatic or with mild symptoms	64 patients diagnosed with COVID-19	100 patients diagnosed with COVID-19
<b>Setting (hospital, ambulatory...)</b>	Ambulatory	Ambulatory	Ambulatory	Hospital
<b>Intervention (generic drug name and dosage)</b>	25,000 IU of vitamin D supplement in addition to usual care	8 capsules of cholecalciferol 50,000 IU	High dose vitamin D: 50,000 IU, Oral Vitamin D3	25,000 IU/ml of cholecalciferol: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36
<b>Comparator (standard care or generic drug name and dosage)</b>	Usual care	8 capsules of placebo	Low dose vitamin D: Vitamin D3 1,000 IU	Placebo
<b>Primary Outcome(s)</b>	Composite of cumulative death (i.e. mortality) for all causes and for specific causes	Patients requiring admission to the hospital or experiencing death	Symptoms recovery	Vitamin D serum concentration****
<b>Sponsor/ lead institution, country (also country of recruitment if different)</b>	Universidad de Granada, Spain	University Hospitals Cleveland Medical Center, US	University of Alberta, USA	University of Liege, Belgium

\*Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

Abbreviations: [RCT]=[randomised clinical trial]; [IU]=[international unit]; [mcg]=[microgram]

\*\*\*\* Mortality is mentioned as secondary outcome measure.

**Table 4-8 Ongoing trials of single agent: Vitamin D, continued**

<b>Trial Identifier/registry ID(s)/contact</b>	NCT04449718	NCT04411446	NCT04536298	NCT04459247
<b>Estimated study completion date</b>	October 2020	December 2020	April 2021	September 2020
<b>Study design, study phase</b>	RCT, phase: no information	RCT, Phase 4	RCT, Phase 3	RCT
<b>Recruitment status</b>	Completed	Recruiting	Recruiting	Not recruiting
<b>Number of Patients, Disease severity*</b>	240 patients diagnosed with COVID-19	1264 patients diagnosed with COVID-19	2700 patients diagnosed with COVID-19	30 patients diagnosed with COVID-19 and present asymptomatic or with mild symptoms
<b>Setting (hospital, ambulatory...)</b>	Hospital	Hospital	Ambulatory	Ambulatory
<b>Intervention (generic drug name and dosage)</b>	Vitamin D: 200,000 IU on admission	5 capsules of 100,000 IU Vitamin D orally given all at once	Vitamin D: Three capsules per day (9,600 IU/day) will be taken on days 1 and 2, and one capsule per day (3,200 IU/day) will be taken on days 3 through 28	Vitamin D: 60,000IU of cholecalciferol (5 ml oral solution in nano droplet form) daily for seven days
<b>Comparator (standard care or generic drug name and dosage)</b>	Placebo	Placebo	Placebo	Only single dose of 60,000 IU vitamin D supplementation
<b>Primary Outcome(s)</b>	Length of hospitalization	Respiratory organ failure assessment score (SOFA) Need of a high dose of oxygen or mechanical ventilation.	Hospitalization or death in index cases	SARS-CoV-2 RNA negative
<b>Sponsor/ lead institution, country (also country of recruitment if different)</b>	Clinical Hospital of the School of Medicine, University of Sao Paulo, Brazil	Vitamin D Study Group; Ag Nac Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina	Brigham and Women's Hospital, USA	Postgraduate Institute of Medical Education and Research, India

\*Mixed COVID-19, Mild, Moderate, Severe, Critical COVID-19

**Abbreviations:** [RCT]=[randomised clinical trial]; [IU]=[international unit]; [ml]=[millilitre]

## 5 REFERENCES

- [1] EFSA. Dietary reference values for vitamin D. 2016.
- [2] Simonson W. Vitamin D dosing considerations in COVID-19. *Geriatric Nursing*. 2020;41(5): 648-9.
- [3] Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019)*: Cochrane; 2019. Available from: <http://www.training.cochrane.org/handbook>.
- [4] Higgins J, Savovic J, Page M, Sterne J. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). RoB2 Development Group; 2019.
- [5] Balshem H HM, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology*. 2011;64: 401-6.
- [6] Sassi F, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. *Nutrients*. 2018;10(11). Epub 2018/11/08.
- [7] Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. *J Clin Endocrinol Metab*. 2013;98(11): 4339-45. Epub 2013/09/05.
- [8] Kalia V, Studzinski GP, Sarkar S. Role of vitamin D in regulating COVID-19 severity—An immunological perspective. *Journal of Leukocyte Biology*.n/a(n/a).
- [9] Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, et al. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. *European Journal of Endocrinology*. 2020;183(5): R133.
- [10] Arboleda JF, Urcuqui-Inchima S. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics? *Frontiers in Immunology*. 2020;11(1523).
- [11] Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? *American Journal of Physiology-Endocrinology and Metabolism*. 2020;318(5): E589-E.
- [12] Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Diaz JF, Lopez Miranda J, Bouillon R, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". *The Journal of steroid biochemistry and molecular biology*. 2020;203: 105751.
- [13] Murai Ih FALSPPAJGKFDCSCSCBRFA. Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: a Multicenter, Double-blind, Randomized Controlled Trial (preprint). *Medrxiv*; 2020. p. 2020.11.16.20232397.
- [14] Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J*. 2020. Epub 2020/11/14.
- [15] Live map of COVID-19 evidence <https://www.fhi.no/en/qk/systematic-reviews-hta/map/>: Oslo: Norwegian Institute of Public Health; [09. February 2021], accessed 09. February 2021.

- [16] COVID-19: a living systematic map of the evidence London: EPPI Centre, University College London; [09. February 2021]; Available from: <http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingssystematicmapofthevidence/tabid/3765/Default.aspx>, accessed 09. February 2021.

## 6 APPENDIX

### 6.1 Search strategy to identify randomised controlled trials

GÖG is responsible for setting up the search strategy to identify randomised controlled trials (RCTs). GÖG performed a search in Medline and PubMed (Appendix Table 6-1) and searched medRxiv.org (<https://www.medrxiv.org/>), bioRxiv.org (<https://www.biorxiv.org/>), and arXiv.org (<https://www.arXiv.org/>) for preprints of preliminary reports of randomised trials. The Cochrane COVID-19 Study Register (<https://covid-19.cochrane.org/>), ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) ISRCTN registry (<https://www.isrctn.com/>) and EU Clinical Trials Register (<https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19+AND+vitamin+D>) were searched in addition. We applied no restriction on language of publication.

**Table 6-1 Search strategy to identify randomised controlled studies**

Database	URL	Search line / Search terms	Date of search
Pubmed	pubmed.ncbi.nlm.nih.gov	1. (((("Coronavirus"[Mesh]) OR (coronavirus*[Title/Abstract] OR coronavirus*[Title/Abstract] OR coronavirinae*[Title/Abstract] OR Coronavirus*[Title/Abstract] OR Coronavirus*[Title/Abstract] OR Wuhan*[Title/Abstract] OR Hubei*[Title/Abstract] OR Huanan[Title/Abstract] OR "2019-nCoV"[Title/Abstract] OR 2019nCoV[Title/Abstract] OR nCoV2019[Title/Abstract] OR "nCoV- 2019"[Title/Abstract] OR "COVID-19"[Title/Abstract] OR COVID19[Title/Abstract] OR "HCoV-19"[Title/Abstract] OR HCoV19[Title/Abstract] OR CoV[Title/Abstract] OR "2019 novel"[Title/Abstract] OR Ncov[Title/Abstract] OR "n-cov"[Title/Abstract] OR "SARS- CoV-2"[Title/Abstract] OR "SARSCoV-2"[Title/Abstract] OR "SARSCoV2"[Title/Abstract] OR "SARS-CoV2"[Title/Abstract] OR SARSCov19[Title/Abstract] OR "SARS-Cov19"[Title/Abstract] OR "SARS-Cov-19"[Title/Abstract] OR Ncovor[Title/Abstract] OR Ncorona*[Title/Abstract] OR (((respiratory*[Title/Abstract] AND (symptom*[Title/Abstract] OR disease*[Title/Abstract] OR illness*[Title/Abstract] OR condition*))OR "seafood market"[Title/Abstract] OR "food market"[Title/Abstract] ) AND (Wuhan*[Title/Abstract] OR Hubei*[Title/Abstract] OR China*[Title/Abstract] OR Chinese*[Title/Abstract] OR Huanan*[Title/Abstract]))) OR ("severe acute respiratory syndrome*")) OR ((corona*[Title/Abstract] OR corono*[Title/Abstract] AND (virus*[Title/Abstract] OR viral*[Title/Abstract] OR virinae*[Title/Abstract]))) AND ((((((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (clinical trials as topic [mesh: noexp]) OR (randomly [tiab]) OR (trial [ti])) NOT (animals [mh] NOT humans [mh]) AND (2019/10/01:2020[dp])) AND ((vitamin D[Title/Abstract] OR high-dose Vitamin D[Title/Abstract]) OR (vitamin D[MeSH Major Topic]))	12/01/2021

Database	URL	Search line / Search terms	Date of search
Ovid MEDLINE(R) ALL	ovidsp.dc2.ovid.com	1 exp coronavirus/ 2 ((corona* or corono*) adj1 (virus* or viral* or virinae*)).ab,kw,ti. 3 (coronavirus* or coronavir* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCov or "HCoV-19" or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or SARSCov19 or "SARSCov19" or "SARSCov-19" or "SARS-Cov-19" or Ncover or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*).ab,kw,ti. 4 (((respiratory* adj2 (symptom* or disease* or illness* or condition*)) or "seafood market*" or "food market*") adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*)).ab,kw,ti. ((outbreak* or wildlife* or pandemic* or epidemic*) adj1 (China* or Chinese* or Huanan*)).ab,kw,ti. 6 "severe acute respiratory syndrome* ".ab,kw,ti. 7 or/1-6 8 randomized controlled trial.pt. 9 controlled clinical trial.pt. 10 "random*".ab. 11 placebo.ab. 12 clinical trials as topic.sh. 13 random allocation.da,sh. 14 trial.ti. 15 or/8-14 16 exp animals/ not humans.sh. 17 15 not 16 18 7 and 17 19 limit 18 to yr="2019 -Current" 20 exp Vitamin D/ 21 vitamin D.ab,kw,ti. 22 high-dose Vitamin C.ab,kw,ti. 23 20 or 21 or 22 24 18 and 23	12/01/2021

## 6.2 Search strategy to identify observational studies (January 2021)

As of October 2020, NIPHNO is responsible for setting up the search strategy to identify observational studies. We receive studies that [EPPI Centre](#) has screened after searching weekly in Medline and Embase. We supplement these studies with a weekly search in Scopus. The retrieved hits were imported into an Endnote database and combined with generic names of the included COVID-19 drugs.

**Table 6-2 Search strategy to identify observational studies**

Database	URL	Search terms / Search modality	Date of search
OVID Medline	Imported from EPPI Centre	1 exp Coronavirus/ 2 exp Coronavirus Infections/ 3 (coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).mp. 4 (or/1-3) and ((2019* or 202*).dp. or 20190101:20301231.(ep.)) 5 4 not (SARS or SARS-CoV or MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or covidence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV or murine corona*).mp. 6 ((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).mp. or exp pneumonia/) and Wuhan.mp. 7 (2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV on nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19 or covid-19) and pandemic*2) or (coronavirus* and pneumonia)).mp. 8 COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os. 9 ("32240632" or "32236488" or "32268021" or "32267941" or "32169616" or "32267649" or "32267499" or "32267344" or "32248853" or "32246156" or "32243118" or "32240583" or "32237674" or "32234725" or "32173381" or "32227595" or "32185863" or "32221979" or "32213260" or "32205350" or "32202721" or "32197097" or "32196032" or "32188729" or "32176889" or "32088947" or "32277065" or "32273472" or "32273444" or "32145185" or "31917786" or "32267384" or "32265186" or "32253187" or "32265567" or "32231286" or "32105468" or "32179788" or "32152361" or "32152148" or "32140676" or "32053580" or "32029604" or "32127714" or "32047315" or "32020111" or "32267950" or "32249952" or "32172715").ui. 10 or/6-9 11 5 or 10	1/12/2020 until 04/01/2021  And from 1/09/2020 until 04/01/2021 for the new compounds Vitamin D, Aspirin and Mavrilimumab
OVID EMBASE		1 exp Coronavirus Infections/ 2 exp coronavirinae/ 3 (coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).mp. 4 or/1-3 5 4 not (SARS or SARS-CoV or MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or covidence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV or murine corona*).mp.	1/12/2020 until 04/01/2021  And from 1/09/2020 until 04/01/2021 for the new compounds Vitamin D, Aspirin and Mavrilimumab

		<p>6 ((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).mp. or exp pneumonia/) and Wuhan.mp.</p> <p>7 (2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV on nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19 or covid-19) and pandemic*2) or (coronavirus* and pneumonia)).mp.</p> <p>8 6 or 7</p> <p>9 5 or 8</p>	
Scopus		<p>TITLE-ABS-KEY(((pneumonia OR covid* OR coronavirus* OR "corona virus*" OR ncov* OR 2019-ncov OR sars*) AND Wuhan) OR 2019-ncov OR ncov19 OR ncov-19 OR "2019-novel CoV" OR sars-cov2 OR sars-cov-2 OR sarscov2 OR sarscov-2 OR sars-coronavirus2 OR sars-coronavirus-2 OR "SARS-like coronavirus*" OR coronavirus-19 OR covid19 OR covid-19 OR "covid 2019" OR ((novel OR new OR nouveau) W/1 (CoV OR nCoV OR covid OR coronavirus* OR "corona virus*" OR pandemi*)) OR ((covid OR covid19 OR covid-19) AND pandemic*) OR ((coronavirus* OR "corona virus*" AND pneumonia)) AND ORIG-LOAD-DATE &gt; 20200920[date changes from week to week] AND ORIG-LOAD-DATE &lt; 20200928 [date changes from week to week] AND NOT INDEX(medline)</p>	<p>1/12/2020 until 04/01/2021</p> <p>And from 1/09/2020 until 04/01/2021 for the new compounds Vitamin D, Aspirin and Mavrilimumab</p>

### 6.3 Search strategy to identify observational studies (February 2021)

As of October 2020, NIPHNO is responsible for setting up the search strategy to identify observational studies.

From September to December 2020, we received records that EPPI Centre has screened after searching weekly in Medline and Embase (until beginning of November 2020), from November onwards Microsoft Academic Graph (MAG). We supplemented these studies with a weekly search in Scopus (Elsevier). Detailed descriptions of the EPPI and NIPHNO searches are given at their websites. [15,16] The retrieved hits were imported to a reference management tool, Endnote (Clarivate Analytics), for deduplication. We then searched the EndNote database using the generic names and synonyms for the included COVID-19 drugs.

From January onwards, an information specialist at NIPHNO has conducted searches in Medline (Ovid), Embase (Ovid) and Scopus (Elsevier) using the search strategy described in table 6.2. To screen the references, two reviewers use a binary machine learning (ML) classifier. References that scored above the identified threshold of 30% certainty to be relevant were retained for screening; while those scoring below this threshold score were set aside.

Prior to using the binary ML classifier score to discard low scoring records, we screened 1028 references manually to train the classifier. The classifier is continuously being updated a long with new references being screened. References that have been set aside, can potentially be picked up in a later stage by a new classifier version. For drugs that have less than 5 publications included in the training batch, we combine the classifier with manual text word searches.

**Table 6-3 Search strategy to identify observational studies**

Database	URL	Search terms / Search modality	Date of search
Embase 1974 to 2021		Lines 1 and 2 are copies of Ovid's Expert searches for covid-19 in MEDLINE and Embase	From 1/9/2020 until 3/2/2021
Ovid MEDLINE(R)		1 (((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).mp. or exp	Covering publication dates 01. September 2020

<p>ALL 1946 to 2021</p>		<p>pneumonia/) and Wuhan.mp.) or (2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or pandemi*2)) or ((covid or covid19 or covid-19) and pandemi*2) or (coronavirus* and pneumonia)).mp. or COVID-19.rx,px,ox,sh. or severe acute respiratory syndrome coronavirus 2.os.) use medall [COVID-19 in MEDLINE]</p> <p>2 (((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).mp. or exp pneumonia/) and Wuhan.mp.) or (coronavirus disease 2019 or 2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or severe acute respiratory syndrome coronavirus 2 or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or pandemi*2)) or ((covid or covid19 or covid-19) and pandemi*2) or (coronavirus* and pneumonia)).mp. or (coronavirus disease 2019 or severe acute respiratory syndrome coronavirus 2).sh,dj.) use oomezd [COVID-19 in Embase]</p> <p>3 (COVID-19 serotherapy/ or Immunization, Passive/ or tocilizumab/ or camostat/ or nafamostat/ or AP301 peptide/ or Interleukin 1 Receptor Antagonist Protein/ or alunacedase alfa/ or darunavir/ or favipiravir/ or sarilumab/ or exp Interferons/ or gimsilumab/ or canakinumab/ or REGN-COV-2/ or bamlanivimab/ or baricitinib/ or molnupiravir/ or Aspirin/ or mavrilimumab/ or exp Vitamin D/dt or Vitamin D Deficiency/dt or Ivermectin/) use medall [MeSH-terms for drugs in MEDLINE]</p> <p>4 (Hyperimmune globulin/dt or tocilizumab/ or camostat/ or camostat mesilate/ or nafamstat/ or solnatide/ or anakinra/ or darunavir/ or favipiravir/ or sarilumab/ or exp Interferon/ or gimsilumab/ or canakinumab/ or baricitinib/ or acetylsalicylic acid/ or mavrilimumab/ or exp Vitamin D/dt or Vitamin D Deficiency/dt or ivermectin/) use oomezd [Emtree-terms for drugs in Embase]</p> <p>5 ((convalescent adj (plasma or sera or serum)) or serotherap* or ((atoxin or hyperimmunoglobulin or hyperimmune globulin or hyperimmune gammaglobulin) adj therap*) or passive immuni?ation or (tocilizumab or atlizumab or (MRA adj monoclonal antibod*) or MSB-11456 or MSB11456 or R-1569 or R1569 or RO-4788533 or RO4788533 or Actemra or Roactemra) or (camostat* or FOY-305 or FOY305 or FOY S 980) or (nafamostat or nafamstat or FUT-175 or FUT175) or (solnatide or AP301 or AP-301 or (TIP adj peptide)) or (anakinra or ((interleukin 1 or IL1 or IL-1) adj2 (antagonist or block* or inhibitor*)) or IL-1Ra or Kineret) or (alunacedase or APN01 or APN-01 or rhACE2 or recombinant human angiotensin</p>
-------------------------	--	--

		<p>converting enzyme 2 or GSK-2586881 or GSK2586881) or (darunavir or prezista or TMC-114 or TMC114 or UIC-94017 or UIC94017) or (favipiravir or T-705 or T705 or Avigan or Olumiant) or (sarilumab or REGN-88 or REGN88 or SAR-153191 or SAR153191 or Kevzara) or (interferon* or (IFN adj1 (alpha* or beta* or gamma*)) or novaferon or CL-884 or CL884) or (gimsilumab or KIN-1901 or KIN1901 or morab-022 or morab022) or (canakinumab or ACZ-885 or ACZ885 or immunoglobulin G1 or Ilaris) or (REGN-CoV-2 or REGN-CoV2 or antibody cocktail or ((casirivimab or REGN-10933 or REGN10933) and (imdevimab or REGN-10987 or REGN10987))) or (bamlanivimab or LY-CoV555 or LYCoV555 or LY-3819253 or LY3819253) or (baricitinib or LY-3009104 or LY3009104 or INCB-028050 or INCB028050 or INCB-28050 or INCB28050 or Olumiant) or (molnupiravir or MK-4482 or MK4482 or EIDD-2801 or EIDD2801) or (aspirin or acetylsalicylic acid) or (mavrilimumab or immunoglobulin G4 or CAM-3001 or CAM3001) or ((vitamin? D? or D?-vitamin?) adj4 (high-dose* or highdose* or supplement*)) or (ivermect* or MK-933 OR MK933)).mp,bt,ot,du,dy,tn,nm. [other terms (title, abstract, author keywords and more) in MEDLINE and Embase]</p> <p>6 (202009* or 202010* or 202011 or 202012* or 202101* or 202102*).dt. use medall [time limits in MEDLINE]</p> <p>7 (202009* or 202010* or 202011 or 202012* or 202101* or 202102*).dc. use oomezd [time limits in Embase]</p> <p>8 (1 and (3 or 5) and 6) use medall</p> <p>9 (2 and (4 or 5) and 7) use oomezd</p>	
--	--	---	--

## 6.4 Search strategy to identify ongoing studies


GÖG is responsible for searching in trial registries to identify ongoing and unpublished studies. The combination of search terms related to COVID-19 and Vitamin D are described in Table 6-4.

**Table 6-4 Search strategy to identify ongoing studies**


Database	URL	Search line / search terms	Date of search	Hits retrieved
ClinicalTrials.gov	<a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a>	“Basic search mode*” Terms used at Condition or disease: <ul style="list-style-type: none"> <li>• covid-19</li> </ul> Terms used at “other terms”: <ul style="list-style-type: none"> <li>• Vitamin D</li> </ul>	12/01/2021	71
ISRCTN	<a href="https://www.isrctn.com/">https://www.isrctn.com/</a>	Basic search mode  Search terms: <ul style="list-style-type: none"> <li>• covid-19 and Vitamin D</li> </ul>	12/01/2021	0
European Clinical Trials Registry	<a href="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</a>	Basic search mode Search terms: <ul style="list-style-type: none"> <li>• covid-19 and Vitamin D</li> </ul>	12/01/2021	0

\* In Basic Search mode, one term was added to the field “condition or disease” and one term in the field “other terms”.

## 6.5 Flow diagrams




**Appendix Figure 6-1. Flow diagram depicting the selection process of RCTs**  
 RCT = randomised controlled trial



**Appendix Figure 6-2. Flow diagram depicting the selection process of observational studies (January 2021)**

\*26 studies evaluating active substances relevant to other EUnetHTA rolling collaborative reviews, 1 study with a vitamin D dosage not fulfilling inclusion criteria



**Appendix Figure 6-3. Flow diagram depicting the selection process of observational studies (February 2021)**

\* studies evaluating active substances relevant to other EUnetHTA rolling collaborative reviews